Compare UTL & FTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UTL | FTH |
|---|---|---|
| Founded | 1984 | N/A |
| Country | United States | United States |
| Employees | N/A | 29 |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 906.9M | 860.0M |
| IPO Year | 1995 | 2021 |
| Metric | UTL | FTH |
|---|---|---|
| Price | $54.32 | $28.19 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $56.50 | N/A |
| AVG Volume (30 Days) | 132.3K | ★ 149.1K |
| Earning Date | 05-04-2026 | N/A |
| Dividend Yield | ★ 3.65% | N/A |
| EPS Growth | ★ 1.37 | N/A |
| EPS | ★ 1.85 | N/A |
| Revenue | ★ $536,000,000.00 | N/A |
| Revenue This Year | $5.43 | N/A |
| Revenue Next Year | $4.22 | N/A |
| P/E Ratio | $29.22 | ★ N/A |
| Revenue Growth | ★ 8.33 | N/A |
| 52 Week Low | $45.11 | $17.50 |
| 52 Week High | $55.59 | $37.90 |
| Indicator | UTL | FTH |
|---|---|---|
| Relative Strength Index (RSI) | 59.81 | 55.37 |
| Support Level | $49.84 | $21.19 |
| Resistance Level | N/A | $37.90 |
| Average True Range (ATR) | 1.17 | 4.38 |
| MACD | 0.11 | -0.13 |
| Stochastic Oscillator | 62.81 | 43.31 |
Unitil Corp through its subsidiaries engages in the distribution of electricity and natural gas in its service territories in the states of New Hampshire, Massachusetts and Maine. Its natural gas operations include gas distribution utility operations and interstate gas transmission pipeline operations. It also engages in interstate natural gas transmission pipeline company, operating approximately 85 miles of underground gas transmission pipeline located in Maine and New Hampshire. The company's segments include Electric and Gas.
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.